Alnylam Pharmaceuticals (FRA:DUL) FFO


FRA:DUL Alnylam Pharmaceuticals Inc FRA:DUL
63 GF Score
Price €273.00
GF Value €453.70
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alnylam Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

FRA:DUL
63GF Score
Alnylam Pharmaceuticals Inc FRA:DUL
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alnylam Pharmaceuticals (FRA:DUL) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of €273.00 is trading 39.8% below its estimated GF Value™ of €453.70. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for FRA:DUL:

  • FFO:
  • GF Value™: €453.70 vs. price of €273.00 (39.8% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the FRA:DUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
63GF Score

Get the complete analysis for FRA:DUL

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€273.00
Price
€453.70
GF Value